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Abstract. The National Organ Transplant Act of 1984 banned compensation for organ 
donation. The ban was interpreted as applying also to bone marrow. An August 2017 
decision by the U.S. Department of Health and Human Services made compensation legal 
for bone marrow. I review the situation regarding compensation for bone marrow donations 
from 1984 to 2017 and describe what has happened so far under legalized compensation. 
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1. Introduction 
one marrow is a soft, spongy tissue located inside the center cavity of 
bones. It is the production site of blood stem cells. These blood stem cells 
can differentiate into white blood cells for immune function, red blood cells 
for the transport of oxygen, or platelets for the prevention of excessive bleeding. 
Because bone marrow has such a varied range of functions within the body it 
has become an important tool in treating various blood cancers and bone marrow 
diseases, as well as immune and genetic diseases. To treat a patient with bone 
marrow, an analysis of the proteins in the patient’s blood is done to find a donor 
who has very similar human leucocyte antigen (HLA). According to the National 
Cancer Institute (NCI), ‚Human leucocyte antigen is a type of molecule found on 
the surface of most cells in the body that plays an important part in the body's 
immune response to foreign substances. They make up a person’s tissue type, 
which varies from person to person.‛ (NCI Dictionary of Cancer Terms ). Once it is 
confirmed that the donor and the patient have almost identical HLAs, bone marrow 
is extracted from the donor and transfused into the patient (National Marrow Donor 
Program, n.d.). 
Bone marrow transplants can generally be classified into one of three 
categories: autologous transplants, allogenic transplants, or haploidentical 
transplants. An autologous transplant, the most common form of bone marrow 
transplant today, is one in which the patient’s own bone marrow is reintroduced 
after having undergone treatment. An allogenic transplant is one in which the 
patient receives bone marrow from a donor who has a very similar HLA type to 
that of the patient (National Marrow Donor Program, n.d.). The last form, a 
haploidentical transplant, is one in which the patient receives bone marrow from 
someone whose HLA matches 50 percent of that of the patient’s. In most cases, 
haploidentical transplants occur between parents and children or between siblings. 
This paper focuses on the issue of bone marrow compensation. It analyzes the 
potential effect that compensation would have on the supply of bone marrow, as 
well as discussing why the United States currently does not have a system by 
which donors can be compensated for donations, even though compensation has 
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been legal since August 2017. The paper focuses on allogenic transplants from 
unrelated donors – meaning situations where the donor and the receipt of the bone 
marrow are not genetically related, but they are a very close HLA match for one 
another – because they are the type of transplants for which abstract economic 
theory suggests that compensation would be the most effective in increasing 
supply.  
 
2. Bone marrow background 
In the last several years, bone marrow has become a topic of interest because 
there is controversy as to whether or not bone marrow donations to unrelated 
recipients should be monetarily compensated. Those who argue in favor of 
compensation claim that bone marrow is no different from blood plasma, eggs, or 
sperm, the donations of which are legal to compensate. Furthermore, compensation 
has been proven to work to increase donations of blood and therefore could be an 
appropriate method to decrease the current scarcity of bone marrow matches. 
Those opposed to compensation argue that it will not only place those of lower 
socioeconomic status at a significant disadvantage if they were to need bone 
marrow, but it would also lead donors in need of money to lie about health 
problems that could potentially render their donation useless (Sibilla, 2016). 
For simplicity, my discussion will designate the patient to be a female and the 
donor to be a male. When a patient is in need of a bone marrow transplant her 
doctor will search the National Bone Marrow Donor Program (NMDP) registry 
called ‚Be the Match‛ for a close match to the patient’s HLA type. This registry 
contains the HLA typing information for all registered donors for a patient in the 
United States (American Society of Clinical Oncology, 2017). 
The NMDP, which was called the National Bone Marrow Donor Registry when 
it started in July 1986, has grown tremendously since its inception. Originally, the 
National Bone Marrow Donor Registry was given a contract through the U.S. Navy 
with enough funds to employ just one full-time employee and to subcontract 
software from the University of Minnesota. The software system was given to 
hospitals for free to allow doctors to be able to search for matches for their patients. 
These beginnings are a far cry from today’s NMDP, which employs over 600 
people and is financially supported by multiple federal contracts organized through 
the Health Resources and Services Administration, an agency of the U.S. 
Department of Health and Human Services (Ballen, et al., 2008). 
The registry works in the following way: an interested donor registers with the 
NMDP through the phone, online, or a third-party campaign. Once he is registered 
he can go to a donor center for a small blood sample or will receive a kit in the 
mail that contains the necessary instruments for a mouth swab. Either of these will 
be sent back to the NMPD, analyzed for the necessary HLA typing information, 
and placed in the database of potential donors. This is the database used by 
physicians at bone marrow transplant centers to find donors when patients are in 
need. Once a patient is a match for a donor in the registry, the donor is contacted 
and asked for a second sample to confirm the accuracy of the match. If the patient’s 
physician verifies the match, the donor is then contacted by a counselor from the 
NMPD. The counselor will discuss with the potential donor the type of procedure 
that the patient’s doctor is recommending and what exactly that entails for the 
donor. This is when the donor decides whether or not he would like to donate his 
bone marrow.5 Often, potential donors choose not to donate. Many economists as 
well as experts in bone marrow donation have suggested that the share of potential 
donors who match but then choose not to donate their bone marrow (about 39 
percent) could be decreased significantly if they were compensated for their 
donation (Barakat, 2016). 
Although everyone who chooses to register to be a potential bone marrow donor 
ends up in the Be the Match registry organized by the NMDP, not all donors 
initially make contact with the NMDP. Many donors register through third-party 
donation campaigns such as Delete Blood Cancers and the Asian American Donor 
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Program (AADP) (Marrow Drives, n.d.). All U.S. registries ultimately list their 
donors in Be the Match, but some recruit outside of Be the Match. Two that make 
large contributions to the NMDP are the Gift of Life Marrow Registry and DKMS. 
Gift of Life is a primarily Jewish registry started in 1991 to help find Jay Feinberg 
a match; to this day it continues to register potential donors. DKMS is a registry 
started in Germany in the 1990s by Dr. Peter Harf, who lost his wife to leukemia; 
his aim is to end blood cancers by finding matches for all patients in need (DKMS, 
nd.). Although Be the Match is a registry that is run by the NMDP, a U.S. national 
program, 47 percent of transplants arranged through the NMDP have either a 
foreign donor or recipient. This is accomplished through partnerships with other 
cooperative registries that work similarly to Be the Match. By working with the 
registries of other countries, the NMDP is able to make a significantly greater 
number of matches for those in need in the United States and abroad (National 
Marrow Donor Program, n.d.). 
Many patients and their families are disappointed when they learn that a 
potential donor has chosen not to donate after being confirmed as a match. In many 
cases these donors are the patient’s best hope for survival, which is why the issue 
of compensation becomes personal for families. Research has shown that 
compensating donors helps to increase the number of donations. Knowing this, 
many families ask their doctors if they can compensate the donor out of pocket 
(Flynn, John Wagner, 2009). 
Up until August 2017, giving compensation was considered a felony punishable 
by up to a $50,000 fine and five years of jail time. This was because the 1984 
National Organ Transplant Act (NOTA) states, ‚It shall be unlawful for any person 
to knowingly acquire, receive, or otherwise transfer any human organ for valuable 
consideration for use in human transplantation if the transfer affects interstate 
commerce.‛ Here ‚organ‛ was interpreted to refer to bone marrow as well (U.S. 
Code, Title 42, Chapter 6A). From 1984 to August 2017 regulation of bone marrow 
under the NOTA was at times contested because it was unclear whether bone 
marrow was correctly categorized as an organ, since the body can replenish bone 
marrow, unlike solid organs (Fund, 2016). The liver can regenerate, but liver 
transplants involve surgery. Other frequently transplanted organs such as kidneys, 
hearts, lungs, and corneas do not regenerate. 
 
3. Bone marrow transplant process  
For people familiar with old-fashioned bone marrow donation, it conjures scary 
images of a large epidural-like needle being placed deep inside the hip bone. This 
procedure is called bone marrow harvesting, and although it used to be the primary 
procedure used for bone marrow transplants, today it is only used in about 30 
percent of transplants. The other 70 percent of transplants use a method called 
peripheral blood stem cell donation (PBSC) (Institute for Justice, n.d.). Below is a 
short description of each procedure, the pre-procedure preparation, and the post-
procedure recovery for the donor as well as the patient. Prior to beginning either 
method, the patient and the donor must successfully complete extensive testing for 
both the patient and the donor to assure optimal health for a transplant and to 
confirm the match is strong. In addition, patients undergo weeks of drug therapy to 
help prepare the immune system for the transplant (Johns Hopkins Medicine, n.d.). 
 
3.1. Bone marrow harvesting  
Once the patient is ready for the transplant, the donor arrives at the hospital the 
day of the transplant and receives anesthesia. Doctors then remove liquid bone 
marrow from the back of the donor’s pelvis using a hallow needle. At this point the 
donor may receive a blood transfusion from blood that he previously donated. 
Once the donor has recovered from anesthesia, he can go home later the same day. 
After the donation, donors often experience soreness in the retrieval spot lasting 
anywhere from a few days to upwards of a week (Health Resources & Services 
Administration, n.d.). Complications from this procedure are rare: 98.5 percent of 
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donors fully recover within a few weeks of the procedure. However, 2.4 percent of 
donors experience more serious side effects from the general anesthesia, or damage 
to the bone, nerve, or muscle in the hip region (Health Resources & Services 
Administration, n.d.). 
 
3.2. Peripheral blood stem cells (PRSC) 
Once the patient is about 5 days away from optimal bone marrow introduction, 
the donor begins to receive daily injections of filgrastim*. This is a protein that 
simulates one naturally produced by the body that transports blood stem cells out 
of the bone marrow and into the blood stream so that there are enough blood stem 
cells in the bloodstream for a transplant. The injections can be given at any local 
clinic. Donors may experience varied side effects from the injections, such as 
nausea, headaches, bone and muscle pain, tiredness, and trouble sleeping. 
However, fewer than 1 percent of donors experience severe side effects from the 
filgrastim shots. Once the number of blood stem cells in the bloodstream has 
reached optimal transplant levels, the donor visits an ‚apheresis center‛ where one 
needle is placed in each arm. One needle removes blood, circulates it through a 
machine that filters the blood stem cells out of the blood, and then the second 
needle returns the blood to the donor. Donation sessions may last anywhere from 
three to eight hours, and in about 96 percent of cases enough blood stem cells to 
meet the recipient’s needs are collected in one session. The remaining 4 percent of 
donations require two to four apheresis sessions that may last between four and six 
hours each. 
Complications associated with the extraction of blood stem cells using this 
method are rare: fewer less than 1 percent of donors experience them. This figure is 
similar to that for donating blood plasma. Complications are mainly associated 
with having to place a central line in donors who lack suitable arm veins. 
Before a patient can receive the donor’s bone marrow, she has to undergo 
necessary drug therapies to remove the malignancy, make space in the bone 
marrow for healthy bone marrow, and prepare the immune system to receive 
foreign bone marrow. Most of the medications involved have strong side effects 
resembling those of chemotherapy. Regardless of how the donor donated the bone 
marrow, the process of giving it to the patient, called infusion, is the same. A 
catheter that had previously been placed to administer drug therapies is now used 
to infuse the donor’s bone marrow into the patient’s bloodstream. Bone marrow 
infusion closely resembles a blood transfusion. During infusion patients may 
experience pain, chills, fever, and hives. After the transplant, patients are given 
drug therapy to limit complications such as infection and rejection. Patients may 
for a time experience lowered immune function, excessive bleeding, nausea, 
vomiting, diarrhea, and mouth sores. After infusion, patients are normally placed 
on a regimen of antibiotics and graft-versus-host disease preventing medications, 
which each have side effects of their own. 
Although preparing for a bone marrow infusion, the actual process of the 
infusion, and the aftermath may have serious side effects, for most patients it is 
their best chance at survival. According to Milliman, a long-established actuarial 
consulting firm, the five-year survival rate for patients who received allogenic bone 
marrow transplants between 2003 and 2010 was 46 percent to 50 percent (Bentley, 
2017). This estimate is a recalculated composite statistic based on the survival rates 
for acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplasia, 
non-Hodgkin’s lymphoma, aplastic anemia, chronic myelogenous leukemia, 
multiple myeloma, and Hodgkin’s disease, which together made up 89 percent of 
the allogenic bone marrow transplants in the United States. Because five-year 
survival rates are typically calculated based on a specific disease, not a treatment, a 
five-year survival rate for patients who needed allogenic bone marrow transplants 
but were unable to get them is not available. 
As mentioned before, there are various types of bone marrow transplants, so not 
all patients in need of a bone marrow transplant are dependent on an unrelated 
Journal of Social and Administrative Sciences 
JSAS, 5(3), V. Vilarino, p.249-262. 
253 
allogenic transplant. However, 25 percent of all bone marrow transplants that 
occurred in the United States from 2010 to 2014 were from donors who were 
unrelated to the patient (Health Resources & Services Administration, 2017). When 
patients cannot find a suitable match on Be the Match, there are two relatively new 
alternatives: the first is the previously mentioned haploidentical transplant, while 
the second is a cord blood transplant. 
A haploidentical transplant is not ideal because much stronger medications, as 
compared to those given to the patient if the unrelated donor is a better match, must 
be given to the already weakened patient in order to prevent graft-versus-host-
disease. Nonetheless, this option provides patients without a match the chance at a 
lifesaving transplant. 
In the case of cord blood transplants, the blood-forming stem cells from the 
placenta and umbilical cord of a newborn (or two newborns if the recipient is an 
adult) are taken—posing no threat to the newborn or the mother—and infused into 
a patient in need. These cells are more ‚naïve‛ than stem cells collected from older 
donors, meaning they will not attack the tissues of the recipient as readily as would 
stem cells from older donors. Accordingly, there is a lower probability of graft-
versus-host-disease, which means the newborn donor(s) and the patient do not have 
to be as close a match as they would in a traditional unrelated allogenic transplant. 
This circumstance greatly increases the number of patients who can benefit from 
cord blood transplants. Cord blood transplants work for all patients in need of bone 
marrow transplants. However, they also involve additional risks because the 
restoration of blood counts for patients with cord blood transplants takes longer 
than it does with both bone marrow transplants and PBSC transplants (Seattle 
Cancer Care Alliance, n.d.). 
 
4. Bone marrow case law 
The National Organ Transplant Act of 1984 (NOTA) was apparently enacted to 
prevent poor Americans or foreigners in poor countries from selling their kidneys 
for a pittance (Sullivan, 1983). The NOTA specified a list of organs covered but 
permitted regulation to extend to others:  
The term ‚human organ‛ means the human (including fetal) kidney, liver, heart, 
lung, pancreas, bone marrow, cornea, eye, bone, and skin or any subpart thereof 
and any other human organ (or any subpart thereof, including that derived from a 
fetus) specified by the Secretary of Health and Human services by regulation.  
The NOTA therefore implicitly regulated the compensation of bone marrow. 
Since 1984, when the NOTA was interpreted as declaring that compensating bone 
marrow donors was illegal, there has been plenty of activity in the legal system 
over whether compensation should be allowed. One of the strongestarguments is 
that at the time the NOTA was enacted, PBSC was not yet available as a method 
for collecting bone marrow for transplants. Because bone marrow harvesting was 
the only method for obtaining bone marrow from a donor, bone marrow donations 
resembled organ donations more than they did blood or plasma donations. 
However, in 1999 PBSC became a widely accepted transplant method, with post-
transplant success rates equal to those of bone marrow harvesting. Years later, 
advocates of compensation began to argue that donating bone marrow though 
PBSC was not much different than donating blood or plasma, for both of which it 
was legal to compensate donors. Moreover, bone marrow transplants consist of 
infusing patients with blood stem cells, not the actual bone marrow, so no solid 
tissue is being taken from one person to another. Furthermore, a donor’s body 
replenishes the donated blood stem cells within four to six weeks of the donation 
date, unlike a solid organ which the donor’s body cannot regenerate. Using these 
arguments, it seemed logical to amend the NOTA or its ancillary regulations to 
exclude bone marrow so that compensation for bone marrow donations would be 
legal (Park, 2012). 
The first notable case to bring up the issue of compensation regarding bone 
marrow was a constitutional challenge filed on October 26, 2009 by the Law 
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Offices of Justin Sobodash and the Institute for Justice on behalf of several 
plaintiffs, including various parents of children in need of bone marrow donations; 
patients; doctors; and an organization with a proposed business plan for 
compensation. The defendant named in the court documents was Eric Holder, the 
Attorney General of the United States at the time. The case was filed in the U.S. 
District Court for the Central District of California, which covers Los Angeles and 
neighboring jurisdictions (Flynn, & Wagner, 2009). 
The plaintiffs argued that the ban against compensation for bone marrow donors 
was unconstitutional because it violated the Due Process Clause of the Fifth 
Amendment of the U.S. Constitution, which states that the federal government does 
not have the power to limit a person’s life, liberty, or property without due process. 
Here ‚due process‛ describes a legal obligation on behalf of the federal 
government and the states to adhere to the law and to use fair procedures when 
applying the law to its citizens (Cornell Law School, 2017). The plaintiffs argued 
that the NOTA violates due process in two ways: (1) It does not give citizens equal 
protection under the law. (2) It violates a citizen’s right to scientifically accepted, 
lifesaving treatment. The plaintiffs supported their first argument by observing that 
the NOTA includes bone marrow but does not include other cell components found 
in blood. They claimed that this was an inequitable protection under the law 
because patients who needed other components found in blood could compensate 
their donors, thus gainingaccess to more donors, but patients in need of bone 
marrow could not, thereby limiting their ability to obtain the lifesaving treatments. 
The plaintiffs supported their second argument by saying that the doctor listed in 
the case had a right to engage in ‚safe, non-experimental, lifesaving medical 
treatment‛ and the NOTA was not allowing him or his patients to exercise that 
right.  
The plaintiffs asked for the court to allow aproposed pilot study by 
MoreMarrowDonors.Org that would have entailed giving an equivalent 
compensation of $3,000 to donors whose bone marrow was most needed. The 
compensation would not have been direct monetary compensation, but instead 
would have taken the form of scholarships, housing allowances, or a donation to a 
charity of the donor’s choosing. The funds were to come from third-party 
philanthropists who had donated to MoreMarrowDonors.Org.  
The plaintiffs added that one of the most prominent arguments against 
compensating donors was the fact that a market could emerge where there would 
be a flow of organs from the poor to the rich. However, that could not be the case 
for bone marrow because the required HLA specificity for bone marrow is much 
higher than that for kidneys and other organs. This is partly what makes finding a 
bone marrow donor so difficult. The high HLA specificity makes it so that there is 
a low probability that donors looking to make fast cash will be a match for a patient 
currently in need. Out of all the donors registered on Be the Match, only 1 in 40 
will be called for additional testing to confirm a match and only 1 in 360 will go on 
to donate. Furthermore, the plaintiffs argued the previously mentioned point that 
unlike organ donations, bone marrow donations do not have to occur through 
invasive means like surgery, further removing bone marrow donations from the 
initial protective intent of the NOTA (Institute for Justice, 2011). 
On December 1, 2011 the Ninth Circuit Court decided that the proposed pilot 
program was legal so long as the blood stem cells were retrieved through PBSC 
and not bone marrow harvesting. This not only allowsfor the proposed pilot 
program but expandsthe definition of compensation to any form of compensation 
so long as it occurs within the jurisdiction of the Ninth Circuit Court, which 
includes all of the following nine states: California, Alaska, Hawaii, Idaho, 
Montana, Nevada, Oregon, Washington, and some U.S. territories (Kramer, 2011). 
In response to the decision by the Ninth Circuit Court, Holder decided to ask the 
court for an en banc review, in which all of the judges that sit on a court are asked 
to hear a case instead of just a select few judges. This is usually done in either very 
complex cases or in cases expected to set a precedent for future cases (Rottenstein 
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Law Group, n.d.). The Ninth Circuit Court as a whole did not grant the en banc 
review, so it upheld the decision made by the three-judge panel declaring that 
compensation was not illegal. After this decision the Supreme Court of the United 
States offered to hear Holder’s case, but he declined to pursue the case up the 
judicial ladder in late June of 2012 (Kramer, 2012). At the time it seemed like this 
was the end and that MoreMarrowDonors.org would be able to begin their registry 
that would allow for compensation of the rarest donors. Here rarest describes 
donors from minority backgrounds that are most often not on the NMDP registry. 
However, in October 2013 the Department of Health and Human Services 
(HHS), urged by the Obama Administration and the Attorney General, proposed a 
new rule that would define ‚organ‛ to include bone marrow cells regardless of the 
form in which they were donated (Bailey, 2017). 
The timing of the proposed rule lined up with the emergence of a new start-up 
company named Hemeos. Started by students at Georgetown Business School, the 
idea behind Hemeos was to directly compensate bone marrow donors in order to 
boost the likelihood of potential donors both registering to be donors and following 
through with their donation. This business plan was different from that of 
MoreMarrowDonors.Org because Hemeos was designed to directly compensate 
donors with monetary payment, not just alternative forms of compensation. Had 
the regulation proposed by the Department of Health and Human Services been 
enacted, Hemeos’ business would have been rendered illegal. In an interview with 
me, Doug Grant, the co-founder of Hemeos, claimed that the proposed change in 
the definition of ‚organ‛ came at the urging of Be the Match in response to 
Hemeos picking up steam. At the time, Hemeos’ software was already being used 
at a couple of hospitals, which threatened Be the Match’s monopoly over the bone 
marrow market (HHS/HRSA, 2017). The department opened the proposed rule to 
public comment until December 2013. The proposal to redefine organ occurred 
right when the first research regarding compensation was about to be published, 
halting the research. This rule was not decided upon until late 2016, when HHS 
approved the change in the definition of ‚organ‛ and passed the rule on to the 
Office of Budget and Management. The Office of Budget and Management never 
approved the rule, meaning that the final rule by the Ninth Circuit Court held and 
the new HHS definition was not valid. Nonetheless, would-be givers and recipients 
of compensation were reluctant to act in the absence of clear guidance. The legal 
limbo continued until August of 2017, when the Trump Administration chose to 
officially rescind the rule, thus effectively confirming the legality of compensation 
(Kramer, 2017). 
The Trump Administration provided no statement offering a rationale for its 
action. President Trump and other members of the administration had stressed their 
interest in reducing regulations, so possibly the bone marrow regulation was an 
application of that policy. The idea of removing the regulation was proposed by at 
least one federal employee, Kurt Schuler, in May 2017, in response to a Trump 
Administration solicitation the previous month for reform suggestions by federal 
employees and by the public (Schuler, 2017). 
Another reason the bone marrow component of the NOTA has been 
controversial is that the NOTA is a federal law, so it may not apply to instances 
where the donor and the recipient are within the same state, in which case state law 
would take precedence. Twelve states (Colorado, Delaware, Georgia, Illinois, 
Indiana, Michigan, New York, Tennessee, Texas, Virginia, West Virginia, and 
Wisconsin) have legislation that does not allow the compensation of bone marrow 
donations through PBSC. The only state that limits the compensation of bone 
marrow donation, as well as cord blood donation, is Delaware (Williams, 2015). 
 
5. Today’s reality  
Although compensation for bone marrow is no longer regulated by the federal 
government, there are many obstacles it must overcome before it becomes 
commonplace. Citizens who live in states that ban it may not be able to participate 
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in either end of compensation. This is due to grey areas between the laws of the 
state governments and the Commerce Clause of the U.S. Constitution. For 
example, a patient living in a state that bans compensation may not be able to 
receive bone marrow from a donor who was compensated, even if the donor lives 
in a state where compensation is allowed, because it breaches the law of the state in 
which the patient lives. However, this exchange constitutes interstate commerce 
since the donor and the patient are not in the same state. These types of legal 
uncertainties often result in cases being heard before the Supreme Court to 
determine precedents for similar scenarios in the future (Monk, n.d.). 
Then there are the practical difficulties. At the moment, no compensatory bone 
marrow registries exist. According to Doug Grant of Hemeos, the main reason for 
that is that the NMDP opposes the compensation of bone marrow. Both 
MoreMarrowDonors.Org and Hemeos, despite having had different business plans 
in the way they were planning on going about compensating donors, were forced to 
close because of procedures indirectly imposed on them by Be the Match. Grant 
told me in an interview that he closed Hemeos in February 2017 because as a 
startup, the fight against regulation was too much for Hemeos to overcome. By the 
time that compensation became unquestionably legal, the startup had run out of 
capital. For compensation to become a reality, there must be registries that are 
willing to compensate. Because the NMDP so strongly opposes compensation, the 
experts I talked to agreed that the only option for a compensatory bone marrow 
registry to exist is for it to be a competitive, parallel registry to that of Be the 
Match.  
This presents other logistical difficulties because currently Be the Match is the 
registry that most, if not all, physicians use when looking for a match for their 
patient. For a new registry to compete with Be the Match, not only would it, like 
Hemeos, have to develop its own software to provide transplant centers with, but it 
would also need to make connections with individual hospitals so that they begin to 
search the registry. Growing a registry to fully compete with Be the Match’s could 
take years given that there is no centralized process by which hospitals partner with 
bone marrow registries. Each hospital would have to make an individual 
partnership with the compensatory registry. Furthermore, there is currently little 
incentive for entrepreneurs to tackle this seemingly daunting startup possibility 
since the entire bone marrow market accounts for only $3 million to $4 million a 
year.    
In Grant’s opinion, the only way for his vision to become a reality would be for 
a large medical center such as Johns Hopkins Medicine or Medstar at Georgetown 
University to undertake the project. It would have to take it upon itself to create the 
necessary software and partner with other similarly large centers. With the medical 
knowledge and household name that these centers could bring to the table, their 
registry could stand a chance against the power that Be the Match currently 
possesses.  
Lastly, as previously mentioned, 47 percent of the matches made by Be the 
Match include either a foreign donor or recipient. Compensation poses a problem 
in those cases because many of the cooperative registries that partner with Be the 
Match are national registries of countries where compensation is not legal. By 
making compensation legal in the United States, some of these partnerships could 
be strained, potentially leading to a significant loss of international matches. All of 
these are barriers that would need to be somehow overcome in order for 
compensation not only to be realistic but also for it to accomplish its goal of 
helping to relieve the scarcity of bone marrow matches. 
 
6. Evidence that compensation increases donation 
Various research initiatives have shown that for bone marrow donation through 
PBSC, because it is less complicated and intrusive than donating solid organs, 
small amounts of compensation can have a positive effect on the number of 
individuals willing to donate. For example, a working paper by three economists 
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written for the National Bureau of Economic Research in August 2012 found that 
compensating bone marrow donors for their time and leave from work would have 
a positive effect on the number of donations (Lacetera, 2012). 
The same authors had an article published in Science in 2013 that presented 
evidence of various studies that had taken place regarding the effect of 
compensation for blood donations on the amount of donations as well as the quality 
(health conditions of those that donated) of the donations. Although the article 
states that much of the evidence collected up until that point was not very reliable, 
it did mention that out of 19 incentive programs (none offered cash since that was 
not allowed at the time) that were looked at, 18 were successful in raising the 
number of blood donations. In programs that the study reviewed, forms of 
compensation were highly varied, ranging from T-shirts to a day of paid leave from 
work. When making an analogy between these findings and what it could imply for 
bone marrow, it is important to note that the incentives were offered for showing 
up to donate, not for actually donating; this is thought to be the major reason why 
the quality of blood samples was not negatively affected. However, this model may 
not be seamlessly applicable to bone marrow donations. The strategy may increase 
the number of people that register to be potential donors, but it may not do 
anything to assure that if they are called to donate they would go through with the 
donation (Lacetera, 2013). 
Moreover, it is a known fact that platelet donations have been increased by 
simply giving donors $5-$15 gift cards. Because bone marrow donations through 
PBSC use the same procedure as platelet donations, it is reasonable to expect that 
the same level of compensation would have similar effects onbone marrow 
donations.  
 
7. Statistics on bone marrow shortages  
Statistics regarding the availability of bone marrow donations make it clear that 
increasing the number of people who register to be potential donors and who go 
through with their donation is crucial. Seventy percent of patients in need of a bone 
marrow transplant from someone other than themselves do not have a match within 
their family. Only 30 percent of patients have family members who are good 
enough matches for a bone marrow transplant. 
 
 
Figure 1. Share of Patients that Find a Donor on the NMDP's Be the Match Registry by 
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The graph shows the current share of matches by race and ethnicity. These 
shares are smaller for mixed-race patients. This is one of the primary reasons why 
some of the biggest registries that work with the Be the Match registry, such as the 
Gift of Life and Asian American Donor Program, are of a specific cultural or 
ethnic origin. Many of these types of registries were started as grass-roots efforts to 
improve recruitment within communities that have large populations of these 
minorities (Kaster, 2014). 
Given these data, it is evident that the Be the Match Registry needs to become 
more diverse to best serve the bone marrow diversity present in American society 
today. One of the biggest arguments given in support of compensation is that the 
many patients of minority racial or ethnic descent need others of the same origin to 
register with Be the Match and to be willing to donate. Oftentimes, these minorities 
would also significantly benefit from small non-monetary forms of compensation 
proposed by MoreMarrowDonors.Org, such as scholarships or housing allowances. 
For these reasons, it is expected that if compensation wereto be made 
commonplace, many of the shares presented above could be significantly increased 
and the lives of more patients in those groups could be saved.  
 
8. Ethical issues 
Registries that aim to compensate bone marrow donors will also face ethical 
issues. Various ethical arguments that have been made against compensation for 
bone marrow. These include that compensation lessens the altruistic nature of the 
donation since people may be inclined to donate not to save the life of a dying 
patient but in order to be paid or compensated; that it implies that the human body 
is a commodity that can be bought and sold, which in turn lessens the value of a 
life; that it would put those of lower socioeconomic status in greater danger of 
being taken advantage of; and that compensating donors from other countries could 
present an issue of informed consent (London, 2017). 
Regarding the argument that compensating bone marrow donors would detract 
the altruistic nature of the action, some critics of bone marrow compensation argue 
that compensation could lead to a decrease in the population of bone marrow 
donors (Hammond, 2016). They argue that by compensating the donation, the 
donation would no longer be an altruistic action, and therefore those who donate 
their bone marrow because it is a ‚good deed‛ might cease to do so. This, 
according to those that argue this position, would decrease the number of donors on 
Be the Match, thus aggravating the shortage of bone marrow. Supporters of 
compensation reply that the current altruistic-only model of bone marrow 
donations does not provide a large enough donor pool for all of those looking for 
donors. Supporters of compensation argue the current altruistic model will never 
allow for a registry that large, since currently only about 2 percent of the U.S. 
population is registered as prospective bone marrow donors. 
The argument that compensating for bone marrow donations devalues human 
life is in practice rooted in religious beliefs, especially from Roman Catholic 
beliefs, although it is also possible to make a purely secular argument to the same 
effect. Many people, including those at Be the Match, believe that paying up to 
$3,000 for lifesaving cells would lead to a commodification of life. Supporters of 
compensation point to all the other forms of legal and acceptable compensation of 
bodily parts: eggs, sperm, hair, and uterus, in the case of surrogate mothers. 
Furthermore, Samuel Hammond of the Niskanen Center argues that allowing the 
compensation ofparticipants in a clinical trial that may very well lead to life-saving 
discoveries is another form of compensating bodily parts. Because compensation 
for these body parts has yet to lead to an obvious devaluing of human life, it is 
unrealistic to assume that compensating bone marrow donations would be different 
(Hammond, 2016). 
With regard to exploitation, opponents of compensation argue that allowing it 
would lead to a system where poor people would subject themselves to potentially 
dangerous procedures just to meet their basic needs. Supporters of compensation 
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counterargue that this thought process is flawed in the case of bone marrow for two 
main reasons. (1) Preventing people of lower socioeconomic status from earning 
income in any way they can perpetuates their existing circumstances. (2) Bone 
marrow donors are not compensated immediately upon registering; thus current 
need would not increase the probability of registration or of receiving 
compensation. Supporters of compensation further argue in fact, that people of 
lower socioeconomic status may not be as willing to donate as critics think, 
because of the costs that donating may impose on them. Oftentimes, individuals 
with lower socioeconomic status have jobs paid by the hour that are less flexible 
than salaried jobs when it comes to taking paid time off from work. By 
compensating these donors for their time, the cost of loss of wages would no longer 
be a potential reason for which they would be prevented from donating. 
Furthermore, because there is a significant lag time between when a potential 
donor actually registers to be a donor and the time they may be called to donate, 
those looking for a guaranteed way of making quick capital could not turn to bone 
marrow donation. 
 
9. Cost-benefit analysis  
It is important to look at the value added of finding a patient’s ideal match and 
from the patient being able to have a bone marrow transplant, comparing it to the 
case of a patient who is not able to have a bone marrow transplant (potentially 
because she could not find an adequate match on Be the Match). Most patients 
(about 58 percent) who need a bone marrow transplant undergo autologous 
transplants, therefore they do not need a donor since the cells come from 
themselves. In 2017, 12,160 patients underwent autologous bone marrow 
transplants.  
Patients who cannot use their own cells for the bone marrow transplants then 
look to family for a match. If no one in the patient’s family is a match, the most 
common option is to look for an ideal match on Be the Match. Unfortunately, not 
all patients can find ideal matches there. In 2017, 9,284 patients underwent 
allogenic bone marrow transplants. However, it is reported that more than 3,000 
died because they could not find a suitable match on the registry (Institute for 
Justice, n.d.). 
For patients who cannot find a donor on Be the Match, their remaining options 
are to undergo either a transplant from cord blood or a haploidentical transplant. As 
previously discussed, the benefit of both of these types of transplants is that the 
HLA match does not have to be as exact, thereby significantly increasing the 
chances of the patient finding a donor. However, patients who use either of these 
methods are athigher risk for bad outcomes than patients who find ideal matches. 
The biggest risk is that the patient may not take the transplant well, in which case 
the body can develop serious graft-versus host disease, which may be fatal.  
According to the Milliman report mentioned earlier, the estimated total cost for 
an allogenic bone marrow transplant in 2017 was $892,700. This figure includes 
pre-procedure hospital stay and medication, the procedure itself, and post-
procedure follow-up medication. Given the large cost of an allogenic bone marrow 
transplant, the amount of $2,000-$3,000 that has been suggested for donor 
compensation is insignificant, especially if it is able to save the lives of around 
3,000 Americans. Given that economists have agreed that the monetary value of 
the average human life varies between $9 million and $10 million, saving 3,000 
lives a year could bring societal benefits of nearly $21 billion (Merrill, 2017). This 
number was determined by valuing a human life at $9 million, the lower end of the 
bracket, and assuming that compensation would occur at $3,000, the higher end of 
the estimated amount.  
A patient who receives bone marrow from an ideal donor – one who is a very 
close match for her – is much more likely to avoid complications after the 
transplant. In terms of cost savings this is important because hospital stays, and 
medications associated with host-versus-graft disease can be costly. Furthermore, 
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patients in need of bone marrow transplants who are unable to find suitable 
matches and have no other alternatives are left to depend on hospice care, which 
can cost up to $10,000 a month (Andrews, 2013). When analyzing this cost as 
compared to that of a bone marrow transplant plus compensation for the donor, it 
would be important to know the average life expectancy for patients who cannot 
find a match, but this does not exist because bone marrow transplantation treats a 
variety of diseases with varying life expectancies (Nichols, 2017). 
 
10. Conclusions  
Compensation for bone marrow donations has been a controversial topic for 
some time now due to its complexity. For thousands of people every year, a bone 
marrow transplant from an unknown donor represents their only chance for 
survival. In these cases, patients and their families are desperate to do anything to 
find a match within the limited time the patient has left. The national bone marrow 
registry, Be the Match, is unable to find ideal matches for all patients in need. The 
success rate varies by race and ethnicity: while white patients will find their ideal 
match on the registry about 75 percent of the time, for black patients, who have the 
lowest match rate, the rate is under 20 percent.  
Supporters of compensating bone marrow donors contend that paying about 
$3,000 in vouchers to be used for scholarships, housing, or other expenses would 
drastically decrease the number of patients waiting for a bone marrow transplant. 
However, significant research has not been done to prove this claim because up 
until August of 2017 compensating bone marrow donors was either illegal or had 
not been clearly determined to be legal. 
The legal status of bone marrow donations has not always been clear. The 
reason the compensation of bone marrow donations was regulated in the first place 
was because of the National Organ Transplant Act. It states that human organs 
cannot be bought or sold. Although it did not explicitly include bone marrow in its 
definition of an organ, the law was interpreted as covering bone marrow, in large 
part because of the way bone marrow was retrieved when the NOTA was written. 
However, bone marrow donation has changed since 1984. Today, 70 percent of 
retrievals occur through the same process as blood platelet retrieval, which it is 
legal to compensate donors for. Because of this, families of patients in need chose 
to pursue a case in the U.S. District Court for the Central District of California to 
ask that bone marrow not be included in the NOTA. After years of legislative back 
and forth, the District Court ruled that organs as referred to in the NOTA should 
not include bone marrow. However, shortly thereafter, the Department of Health 
and Human Services redefined organs to include bone marrow, thereby halting 
experiments in the field of compensation. Nonetheless, the Office of Management 
and Budget never approved the rule, so the District Court ruling stayed in place. 
The ambiguity surrounding this issue was finally laid to rest when in August 2017 
the Trump Administration officially deregulated the compensation of bone marrow 
(Definition of Human Organ Under, 1984). 
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